Skip to content

Efficacy of Novel Blue Silver Nanoparticles Hydrogel versus Reference Hydrogel: A Prospective Randomized Controlled Trial for Acute and Chronic Wound Management

Comparing the Efficacy of a Novel Blue Silver Nanoparticles Hydrogel versus Reference Hydrogel: A Prospective Randomized Controlled Trial for Acute and Chronic Wound Management

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230623001
Enrollment
60
Registered
2023-06-23
Start date
2017-09-20
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who have acute or chronic partial- or full- thickness wounds and wounds due to thermal burns and accidental injury were included. Acute or chronic wounds Partial or full thickness wound

Interventions

The blue AgNPs hydrogel group was a group that was applied the blue silver nanoparticles hydrogel on the wound once daily. Then, the wound was evaluated at day 0, 7, 14, and 21 after initiation.,The r
Experimental Drug,Active Comparator Drug
The Blue AgNPs Hydrogel Group,The Reference Hydrogel

Sponsors

Novatec Healthcare Co.,Ltd.
Lead Sponsor
The National Innovation Agency (NIA) of Thailand
Collaborator

Eligibility

Sex/Gender
All
Age
10 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All participants were required to be more than 10 years of age and have acute or chronic partial- or full-thickness wounds 2. wounds due to thermal burns and accidental injury were included.

Exclusion criteria

Exclusion criteria: 1. Patients were pregnant, allergic to hydrogel or silver. 2. Patients had a compromised immune system, or had any other connective tissue disease. 3. Infected wounds with frank pus or necrotic tissues were also excluded.

Design outcomes

Primary

MeasureTime frame
wound area reduction (wound healing) on days 0, 7, 14, and 21 after treatment initiation % wound area reduction

Secondary

MeasureTime frame
pain intensity on days 0, 7, 14, and 21 after treatment initiation 10-point visual analogue scale score,infection prevention at day 0, 7, 14, and 21 after treatment initiation wound swab culture

Countries

Thailand

Contacts

Public ContactPornthep Sirimahachaiyakul

Faculty of Medicine Vajira Hospital, Navamindradriraj University

pornthep.sirimahachaiyakul@gmail.com022443282

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026